The SGLT2 Inhibitor, Empagliflozin, Attenuates Some Markers of Renal Fibrosis without Improving Albuminuria in Diabetic Db/Db Mice

被引：0

作者：

Gallo, Linda A. ^{[1
]}

Ward, Micheal S. ^{[1
]}

Fotheringham, Amelia K. ^{[1
]}

Zhuang, Aowen ^{[1
]}

Koepsell, Hermann ^{[2
]}

Vallon', Volker ^{[3
,4
]}

Pollock, Carol ^{[5
]}

Panchapakesan, Usha ^{[5
]}

Forbes, Josephine M. ^{[1
]}

机构：

[1] Univ Queensland, Mater Res Inst, Woolloongabba, Qld, Australia

[2] Univ Wurzburg, Wurzburg, Germany

[3] Univ Calif San Diego, La Jolla, CA 92093 USA

[4] VA San Diego Healthcare Syst, San Diego, CA USA

[5] Univ Sydney, Kolling Inst Med Res, St Leonards, NSW, Australia

来源：

FASEB JOURNAL | 2016年 / 30卷

关键词：

D O I：

暂无

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

740.18

引用

页数：2

共 50 条

[31] Empagliflozin, SGLT2 inhibitor, attenuates renal fibrosis in rats exposed to unilateral ureteric obstruction: potential role of klotho expression
Noha A. T. Abbas
Amal El. Salem
Mohammed M. Awad
Naunyn-Schmiedeberg's Archives of Pharmacology, 2018, 391 : 1347 - 1360
[32] Catalpol alleviates renal damage by improving lipid metabolism in diabetic db/db mice
Jiang, Pingping
Xiang, Lei
Chen, Zewei
Lu, Hanqi
Zhou, Lin
Yang, Lebin
Ji, Yanzhao
Liu, Yanyan
Sun, Xiaomin
Deng, Yingfeng
Nie, Xiaoli
Luo, Ren
Zhao, Xiaoshan
AMERICAN JOURNAL OF TRANSLATIONAL RESEARCH, 2018, 10 (06): : 1750 - 1761
[33] Treatment with SGLT2 Inhibitor Empagliflozin Modulates Renal Sympathetic Nerve Activity in Diabetic Rabbits
Gueguen, Cindy
Burke, Sandra
Barzel, Benjamin
Lim, Kyungjoon
Eikelis, Nina
Watson, Anna
Jha, Jay
Jackson, Kristy
Sata, Yusuke
Lambert, Gavin
Jandeleit-Dahm, Karin
Cooper, Mark
Thomas, Merlin
Geoffrey, A.
FASEB JOURNAL, 2020, 34
[34] The SGLT2 inhibitor Empagliflozin promotes post-stroke functional recovery in diabetic mice
Ellen Vercalsteren
Dimitra Karampatsi
Carolina Buizza
Thomas Nyström
Thomas Klein
Gesine Paul
Cesare Patrone
Vladimer Darsalia
Cardiovascular Diabetology, 23
[35] The SGLT2 inhibitor Empagliflozin promotes post-stroke functional recovery in diabetic mice
Vercalsteren, Ellen
Karampatsi, Dimitra
Buizza, Carolina
Nystrom, Thomas
Klein, Thomas
Paul, Gesine
Patrone, Cesare
Darsalia, Vladimer
CARDIOVASCULAR DIABETOLOGY, 2024, 23 (01)
[36] Gut Microbiota Changes by an SGLT2 Inhibitor, Luseogliflozin, Alters Metabolites Compared with Those in a Low Carbohydrate Diet in db/db Mice
Hata, Shinnosuke
Okamura, Takuro
Kobayashi, Ayaka
Bamba, Ryo
Miyoshi, Tomoki
Nakajima, Hanako
Kitagawa, Nobuko
Hashimoto, Yoshitaka
Majima, Saori
Senmaru, Takafumi
Okada, Hiroshi
Ushigome, Emi
Nakanishi, Naoko
Takakuwa, Hiroshi
Sasano, Ryoichi
Hamaguchi, Masahide
Fukui, Michiaki
NUTRIENTS, 2022, 14 (17)
[37] The SGLT2 inhibitor empagliflozin ameliorates early features of diabetic nephropathy in BTBR ob/ob type 2 diabetic mice with and without hypertension
Gembardt, F.
Bartaun, C.
Jarzebska, N.
Mayoux, E.
Todorov, V. T.
Hohenstein, B.
Hugo, C.
DIABETOLOGIA, 2014, 57 : S332 - S332
[38] The SGLT2 inhibitor empagliflozin ameliorates early features of diabetic nephropathy in BTBR ob/ob type 2 diabetic mice with and without hypertension
Gembardt, Florian
Bartaun, Christoph
Jarzebska, Natalia
Mayoux, Eric
Todorov, Vladimir T.
Hohenstein, Bernd
Hugo, Christian
AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY, 2014, 307 (03) : F317 - F325
[39] CDA1(TSPYL2) Deficiency Attenuates Kidney Fibrosis and Inflammation in db/db Diabetic Mice
Tang, Jiali
Huang, Minling
Wu, Tieqiao
Cooper, Mark E.
Chai, Zhonglin
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2024, 35 (10):
[40] COMBINATION TREATMENT WITH LISINOPRIL AND EMPAGLIFLOZIN IMPROVES BIOCHEMICAL AND HISTOLOGICAL MARKERS OF DIABETIC NEPHROPATHY IN HYPERTENSIVE UNINEPHRECTOMIZED DB/DB MICE
Ostergaard, Mette Viberg
Christensen, Michael
Secher, Thomas
Skytte, Jacob Lercke
Roostalu, Urmas
Salinas, Casper Gravesen
Sembach, Frederikke Emilie
Jelsing, Jacob
Fink, Lisbeth N.
Vrang, Niels
NEPHROLOGY DIALYSIS TRANSPLANTATION, 2021, 36

← 1 2 3 4 5 →